ArticleBMC cancer2026
Assessing the prognostic value of SIL1 in pan-cancer cohorts and its practical application as a biomarker in glioma practice.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGliomas are aggressive brain tumors associated with a poor prognosis. Although SIL1, an endoplasmic reticulum chaperone factor, is known to maintain protein homeostasis, its specific role in glioma pathogenesis remains poorly understood. This study aimed to investigate the clinical significance and biological functions of SIL1 in glioma.
methodsWe performed a pan-cancer multi-omics analysis using TCGA and GTEx datasets to evaluate SIL1 expression, its prognostic value, and its associations with genomic instability, tumor stemness, and immune infiltration. Gene set enrichment analysis (GSEA) was utilized to identify potentially involved signaling pathways. For in vitro functional validation, human glioma cell lines (U251 and A172) were subjected to siRNA-mediated knockdown and lentiviral rescue assays to assess cellular proliferation, migration, apoptosis, and epithelial-mesenchymal transition (EMT) dynamics.
resultsSIL1 was significantly upregulated in gliomas and correlated with poor patient survival. High SIL1 expression was associated with increased tumor heterogeneity (based on MATH scores), DNA methylation-derived stemness indices, and an immunosuppressive microenvironment characterized by the enrichment of M2 macrophages, regulatory T cells (Tregs), and immune checkpoint molecules. In vitro, SIL1 knockdown suppressed glioma cell proliferation and invasion, promoted mitochondrial apoptosis, and mitigated the EMT phenotype, potentially by impairing SNAIL nuclear translocation. Notably, these phenotypic changes were effectively rescued following lentiviral overexpression of SIL1.
conclusionOur findings suggest that SIL1 is a potential prognostic biomarker in glioma. Its elevated expression correlates with increased malignancy, stemness features, EMT, and an immunosuppressive microenvironment, indicating that SIL1 may serve as a promising therapeutic target for glioma intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.